9 research outputs found
EBioMedicine
Background High HIV-1 DNA levels in peripheral blood mononuclear cells (PBMC) were associated with a higher risk of severe morbidity and a faster decline in CD4 count in ART-naive patients. We report the association between HIV-1 DNA and mortality in HIV-infected adults in a trial of early ART in West Africa. Methods In the Temprano trial, HIV-infected adults were randomly assigned to start ART immediately or defer ART. After trial termination, HIV-1 DNA was measured in whole blood samples frozen at baseline. We analyzed the association between baseline PBMC HIV-1 DNA and long-term mortality
Dissection aortique anevrismale chez un adulte infecte par le VIH-1 dans le cadre d'un syndrome de reconstitution immune avec tuberculose
We here report the case of a 35-year old man with HIV-1 but with no previous medical-surgical history hospitalized in Abidjan, Cote d'Ivoire, due to fever, cough, dyspnea, chest pain and unfolding of the aortic arch observed on chest x-ray a week after having started antiretroviral therapy (ART). CT angiography of the thoracic aorta showed overall, extended aortic ectasia with mural thrombus. Transesophageal echocardiography objectified type A ascending aortic dissection (Stanford classification). The diagnosis of tuberculosis was confirmed based on Mycobacterium tuberculosis culture isolation. Eight years after, the patient was still alive without surgical treatment and complained of intermittent chest pain. Blood pressure was stable with moderate renal failure. We here report a rare case of aortic aneurism dissection in an adult patient with tuberculosis infected with HIV-1 during immune reconstitution inflammatory syndrome
Plasma sVCAM-1, antiretroviral therapy and mortality in HIV-1-infected West African adults
OBJECTIVES: We report the association between pre-antiretroviral therapy (pre-ART) soluble vascular cell adhesion molecule-1 (sVCAM-1) levels and long-term mortality in HIV-infected West African adults participating in a trial of early ART in West Africa (Temprano ANRS 12136 trial). METHODS: The ART-naĂŻve HIV-infected adults were randomly assigned to start ART immediately or defer ART until the WHO criteria were met. Participants who completed the trial follow-up were invited to participate in a post-trial phase (PTP). The PTP end-point was all-cause death. We used multivariable Cox proportional models to analyse the association between baseline sVCAM-1 and all-cause death, adjusting for ART strategy, sex, CD4 count, plasma HIV-1 RNA and peripheral blood mononuclear cell HIV-1 DNA levels. RESULTS: In all, 954 adults (77% women, median CD4 count of 387 cells/ÎŒL) were randomly assigned to start ART immediately (n = 477) or to defer initiation of ART (n = 477). They were followed for a median of 5.8 years [interquartile range (IQR): 5.2-6.3]. In multivariable analysis, the risk of death was significantly associated with baseline sVCAM-1 [â„1458 vs. < 1458 ng/mL; adjusted hazard ratio = 2.86, 95% confidence interval (CI): 1.60-5.11]. The 6-year probability of death rates were 14.4% (95%CI: 9.1-22.6) and 9.4% (5.4-16.1) in patients with baseline sVCAM-1 â„ 1458 ng/mL randomized to deferred and immediate ART, respectively, and 3.8% (2.2-6.5) and 3.5% (1.9-6.3) in patients with baseline sVCAM-1 < 1458 ng/mL randomized to deferred and immediate ART. The median difference between pre-ART and 12-month sVCAM-1 levels in patients randomized to immediate ART was -252 (IQR: -587 to -61). CONCLUSIONS: Pre-ART sVCAM-1 levels were significantly associated with mortality, independently of whether ART was started immediately or deferred, but they significantly decreased after 12 months of ART
J Viral Hepat
BACKGROUND: It is unknown how past and active hepatitis B virus (HBV) infection affect immunorecovery and mortality in people with HIV who initiate tenofovir-based anti-retroviral therapy (ART). METHODS: Using data collected between 2008- 2015, we studied people with HIV in sub-Saharan Africa initiating immediate ART in the Temprano randomized control trial. We classified participants into HBV groups at ART-initiation: hepatitis B surface antigen (HBsAg)-positive with HBV DNA â„2000 IU/mL; HBsAg-positive with HBV DNA <2000 IU/ml; isolated HBcAb-positive; resolved infection (HBsAb-positive/HBcAb-positive); and HBV non-immune/vaccinated (HBcAb-). We compared square-root CD4-cell count increases using a mixed-effect, non-linear regression adjusted for age, sex, baseline CD4 cell count, and HIV RNA. We compared all-cause mortality using Bayesian parametric survival regression. RESULTS: Among 879 participants, 24 (2.7%) had HBsAg with high HBV DNA, 76 (8.6%) HBsAg with low HBV DNA, 325 (37.0%) isolated anti-HBcAb, 226 (25.7%) resolved HBV infection, and 228 (25.9%) HBV non-immune/vaccinated. We found no significant difference in CD4 cell increases between the four HBV-infection groups after adjustment (p=0.16). Participants with HBsAg and high HBV DNA had the highest incidence of all-cause mortality [1.9/100 person-years, 95%Credibile Interval (CrI)=1.0-3.4]. By comparison, incidence rates of mortality were reduced by 57% (95%CrI=-79%,-13%), 60% (95%CrI=-82%,-12%), and 66% (95%CrI=-84%,-23%) in those who had isolated anti-HBcAb-positive, resolved HBV infection, and HBV non-immune/vaccinated, respectively. CONCLUSION: Individuals with HIV and past HBV infection or isolated anti-HBcAb-positive serology, much like HBV non-immune/vaccinated, experience lower mortality than those with HBsAg and high HBV DNA. Additional HBV-related management would not be necessary for these individuals
Chimioprophylaxie antituberculeuse primaire Ă l'isoniazide : une stratĂ©gie d'actualitĂ© Ă lâĂšre du tester et traiter ; revue de la littĂ©rature
Position du problĂšme : La tuberculose demeure une menace de santĂ© publique responsable de plus d'un million de dĂ©cĂšs en 2018. La chimioprophylaxie Ă l'isoniazide est une des stratĂ©gies permettant le contrĂŽle de cette maladie. Encore peu prescrite, son intĂ©rĂȘt suscite encore plus de questions Ă lâĂšre du « tester et traiter » concernant les antirĂ©troviraux. L'objectif de cette Ă©tude est donc de rĂ©aliser une revue des essais randomisĂ©s de chimioprophylaxie antituberculeuse primaire Ă l'isoniazide (« thĂ©rapie prĂ©ventive Ă l'isoniazide », TPI), en distinguant les « essais d'efficacitĂ© (EE) » comparant la TPI Ă un placebo ou Ă l'absence de chimioprophylaxie ; et les « essais de rĂ©gime » (ER), comparant la TPI Ă un ou plusieurs autres rĂ©gimes. MĂ©thodes : Recherche bibliographique (mots-clĂ©s sur les bases de donnĂ©es des articles publiĂ©s Medline, Scopus : « tuberculosis », « prophylaxis », « HIV », « randomized controlled trial ») et lecture standardisĂ©e d'articles sĂ©lectionnĂ©s rapportant des rĂ©sultats d'essais randomisĂ©s de TPI chez les personnes infectĂ©es par le VIH. RĂ©sultats : Au total, 18 essais retenus (11 EE et 7 ER), incluant 19 725 participants. Les rĂ©gimes Ă©tudiĂ©s Ă©taient 3H, 6H, 9H, 12H, 36H/2RZ, 3RH, 3RZ, 3RHZ, et 3HP [H : Isoniazide, R : Rifampicine, Z : Pyrazinamide, P : Rifapentine]. Localisation : dix en Afrique, trois Ă HaĂŻti, un en Inde, un aux USA, un aux AmĂ©riques et deux multi continentaux. Dans les EE avec ou sans ARV, la TPI rĂ©duit significativement le risque de tuberculose de 32 % Ă 71 %. Dans les EE avant les ARV, on ne retrouve aucune tendance Ă une rĂ©duction de la mortalitĂ© par la TPI. Dans les EE sous ARV, la TPI rĂ©duit la mortalitĂ©. Dans les ER, on ne trouve aucun argument pour prĂ©fĂ©rer un autre rĂ©gime Ă la TPI. La tolĂ©rance est bonne. La TPI diminue possiblement le risque de sĂ©lection de bacilles multirĂ©sistants, au lieu de l'aggraver, par la baisse du nombre d'Ă©pisodes de tuberculose et donc de l'utilisation des traitements antituberculeux curatifs. Conclusion : Loin d'avoir Ă©tĂ© rendue obsolĂšte par le traitement ARV, la TPI reste une intervention d'actualitĂ©.BACKGROUND: Tuberculosis remains a public health threat responsible as recently as 2018 for more than one million deaths. Chemoprophylaxis with isoniazid is one of the strategies implemented to control the disease. Although it is not yet widely prescribed, its utilization raises additional questions in the "test and treat" era of for anti-retroviral therapy. The objective of this study is to review the different randomized controlled trials of antitubercular Isoniazid Preventive Therapy (IPT). We have distinguished (a) "efficacy trials" (ET) comparing IPT to a placebo or the absence of chemoprophylaxis and (b) "IPT regimen trials" (RT) comparing IPT to one or several other regimens. METHODS: Literature search (keywords from published articles found in the Medline and Scopus data bases: "tuberculosis", "prophylaxis", "HIV", "randomized controlled trial") and standardized reading of selected articles reporting results from randomized trials of IPT in HIV-infected people. RESULTS: Eighteen selected trials (11 ET and 7 RT), including 19,725 participants. The regimens studied were 3H, 6H, 9H, 12H, 12H, 36H/2RZ, 3RH, 3RZ, 3RHZ, and 3HP [H: Isoniazid, R: Rifampicin, Z: Pyrazinamide, P: Rifapentine]. LOCATIONS: Ten in Africa, three in Haiti, one in India, one in the USA, one in the Americas and two multi-continental trials. In ET with or without antiretrovirals (ART), IPT significantly reduces the risk of tuberculosis, by 32 to 71%. In ET prior to ART, IPT does not appear to reduce mortality. In ET in patients receiving ART, on the other hand, IPT reduces mortality. As regards RT, there seems to be no reason to prefer other regimens to IPT. Tolerance is good. Importantly, IPT may reduce (rather than worsen) the risk of multidrug-resistant bacilli selection by decreasing the number of TB episodes and, consequently, the number of curative tuberculosis treatments. CONCLUSION: Far from becoming obsolete due to ARV treatment, IPT has remained a timely and relevant intervention
Association of cellular HIV-1 DNA and virological success of antiretroviral treatment in HIV-infected sub-Saharan African adults
BACKGROUND: HIV-1 DNA persists in infected cells, forming viral reservoirs. Pre-antiretroviral treatment (ART) HIV-1 DNA load was reported to predict ART success in European severely immunocompromised patients. The aim of this study was to determine whether HIV-1 DNA levels are associated with virological success in less severely immunocompromised patients who receive early ART in sub-Saharan Africa. METHODS: The association between pre-ART HIV-1 DNA and the virological response after 30Â months on ART was studied in multivariate logistic regression in patients randomised to immediate ART groups in the Temprano trial, which assessed the benefits of early ART in HIV-infected adults in CĂŽte d'Ivoire. HIV-1 DNA was quantified in peripheral blood mononuclear cell (PBMC) using real-time PCR. RESULTS: HIV-1 DNA levels were measured in 1013 patients. Their medians [IQR] of pre-ART CD4 count, HIV-1 RNA and HIV-1 DNA levels were 465 [379-578]/mm(3), 4.7 [4.0-5.3] log(10) copies/ml and 2.9 [2.5-3.2] log(10) copies/million PBMC, respectively. Pre-ART HIV-1 DNA was significantly correlated with pre-ART HIV-1 RNA (Râ=â0.59, pâ<â0.0001). In multivariate analysis, HIV-1 DNAâ<â3 log(10) copies/million PBMC was significantly associated with virological success at M30 after adjustment for other key variables (ART regimen, IPT, sex, age, WHO clinical stage, CD4 and HIV-1 RNA; aOR 1.57; 95% CI 1.08-2.30; pâ=â0.02). CONCLUSION: Low HIV-1 DNA was statistically associated with virological success in this population of sub-Saharan African adults who started treatment with a median pre-ART CD4 count at 465/mm(3). HIV-1 DNA could become a useful tool for guiding some therapeutic decisions in the test-and-treat era. Trial registration TEMPRANO ANRS 12136 ClinicalTrials.gov, number NCT00495651, date of registration 03/07/2007
Virological failure and drug resistance in West African HIV-infected adults who started ART immediately or deferred ART initiation
BACKGROUND: Asymptomatic HIV-infected people who start ART early may feel less motivated and neglect compliance. This might promote the emergence of resistance. METHODS: In the Temprano trial, ART-naive HIV-infected adults with high CD4 counts were randomly assigned to start ART immediately (immediate group) or defer ART until the WHO criteria were met (deferred group). All participants were monitored for 30âmonths. Those in the deferred group who started ART were monitored for longer, until they had completed 30âmonths on ART. We compared the rate of virological failure and drug resistance between the immediate and deferred groups 30âmonths after ART initiation. RESULTS: Of the 2056 participants in Temprano, 1033 were assigned to start ART immediately and 1023 to defer ART. Of the latter, 488 started ART during trial follow-up. Patients in the deferred group who started ART had a lower median CD4 count (280 versus 465âcells/mm3) and a higher median plasma HIV-1 RNA (5.1 versus 4.7 log10âcopies/mL) at baseline. During follow-up, participants in both groups had similar antiretroviral drug exposure. Thirty months after ART initiation, patients in the deferred group had a higher rate of virological failure (35.3% versus 29.9%, Pâ=â0.04) and a lower genotypic susceptibility score (Pâ=â0.04). CONCLUSIONS: Starting ART early decreases the risk of virological failure and drug resistance in the medium term. This benefit is of particular importance in countries where access to viral load monitoring and the number of antiretroviral drug lines is limited
Transactions of the Royal Society of Tropical Medicine and Hygiene
Background In human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients from sub-Saharan Africa with hepatitis B e antigen (HBeAg)-negative status, data are limited on the evolution of HBV activity when antiretroviral treatment (ART) is absent. Methods A total of 43 HBeAg-negative co-infected patients not indicated for ART (per concomitant World Health Organization recommendations) were followed during participation in a randomized controlled trial in Cote d'Ivoire. Chronic HBeAg-negative phases were classified at yearly visits and defined as infection' (HBV DNA 10 000 copies/mL and/or above normal ALT). Dispersion in HBV DNA and ALT levels during follow-up was assessed using interquartile range (IQR) regression. Results During a median 25 months (IQR 19-31), 17 (40%) patients consistently had infection', 5 (12%) consistently had hepatitis' and 21 (48%) fluctuated between phases. Wider dispersion in HBV DNA over time was associated with higher baseline HIV RNA (p=0.02) and higher baseline HBV DNA levels (p=0.008), while wider dispersion in ALT was associated with higher baseline HIV RNA (p4.0 log(10) IU/mL (p=0.02). Conclusions HBV activity is common with HBeAg-negative status, whose variation is partly linked to HIV replication. Fluctuations in disease phase make it difficult to assess the risk of morbidity and mortality after ART initiation